A clinical-stage biotechnology company in immunotherapy

Focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.

Our latest press release

Read more

21/11/2022

OSE Immunotherapeutics Announces Publication of Peer-Reviewed Data on CLEC-1, its Novel Myeloid Immune Checkpoint in ‘Science Advances’

Download

To receive OSE Immunotherapeutics’ latest news